Overall Score

Threat Of New Entrants

High R&D intensity and regulatory hurdles continue to raise barriers to entry in the lung-device market.

LUNG’s current ratio of 4.32 suggests adequate liquidity to sustain commercialization and defend its position.

Bargaining Power Of Suppliers

No material change: supplier leverage remains balanced by the company’s scale and cash position.

Gross margin remains strong at 77.1%, indicating some ability to absorb input-cost pressure.

Bargaining Power Of Buyers

Hospitals and clinicians retain meaningful negotiating power due to reimbursement sensitivity and purchasing discipline.

Negative profitability and cash flow metrics limit pricing power, keeping buyer leverage elevated.

Threat Of Substitutes

Alternative diagnostic and treatment pathways remain a persistent substitute risk in pulmonary care.

No material change: the company still needs clinical differentiation to reduce substitution risk.

Industry Rivalry

Rivalry remains moderate as the market is still shaped by product adoption, clinical evidence, and reimbursement access.

Negative EBIT margin of -50.0% and net margin of -55.0% suggest the company is still competing in a costly, contested environment.